STOCK TITAN

[6-K] Universe Pharmaceuticals Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Filing overview: On 29 Jul 2025 Orin Hirschman and AIGH Capital Management LLC filed Amendment No. 1 to Schedule 13G on Verastem, Inc. (VSTM). The amendment reports aggregate beneficial ownership of 2,003,179 common shares, representing 3.6 % of Verastem’s outstanding stock as of 30 Jun 2025.

Key details

  • All shares are held with sole voting and dispositive power; no shared power is reported.
  • Item 5 states the group now owns “5 percent or less” of the class, indicating the stake has fallen below the 5 % threshold that triggered the original Schedule 13G.
  • The shares are owned by AIGH Investment Partners, L.P. and WVP Emerging Manager Onshore Fund, LLC – AIGH Series, for which AIGH Capital acts as adviser; Hirschman signs as managing member.

Investor take-away: A former 5 %-plus holder has reduced its position to 3.6 %. While the group remains a meaningful shareholder, the trim may signal lower conviction or portfolio rebalancing; the reduced stake also lessens any single-holder influence over corporate decisions.

Panoramica della comunicazione: Il 29 luglio 2025 Orin Hirschman e AIGH Capital Management LLC hanno presentato l'Emendamento n. 1 al Schedule 13G relativo a Verastem, Inc. (VSTM). L'emendamento riporta una proprietà aggregata di 2.003.179 azioni ordinarie, pari al 3,6% del capitale sociale di Verastem al 30 giugno 2025.

Dettagli principali

  • Tutte le azioni sono detenute con potere di voto e dispositivi esclusivi; non è riportato alcun potere condiviso.
  • L'elemento 5 indica che il gruppo ora possiede “5 percento o meno” della categoria, segnalando che la quota è scesa al di sotto della soglia del 5% che ha innescato il Schedule 13G originale.
  • Le azioni sono detenute da AIGH Investment Partners, L.P. e WVP Emerging Manager Onshore Fund, LLC – AIGH Series, per i quali AIGH Capital agisce come consulente; Hirschman firma come membro amministratore.

Considerazioni per l'investitore: Un ex detentore con oltre il 5% ha ridotto la propria posizione al 3,6%. Sebbene il gruppo resti un azionista significativo, la riduzione potrebbe indicare una minore convinzione o un riequilibrio del portafoglio; la quota ridotta diminuisce inoltre qualsiasi influenza di un singolo azionista sulle decisioni aziendali.

Resumen de la presentación: El 29 de julio de 2025, Orin Hirschman y AIGH Capital Management LLC presentaron la Enmienda n.º 1 al Schedule 13G sobre Verastem, Inc. (VSTM). La enmienda reporta una propiedad agregada de 2.003.179 acciones ordinarias, representando el 3,6 % del capital social en circulación de Verastem al 30 de junio de 2025.

Detalles clave

  • Todas las acciones se mantienen con poder exclusivo de voto y disposición; no se reporta poder compartido.
  • El punto 5 indica que el grupo ahora posee “5 por ciento o menos” de la clase, señalando que la participación ha caído por debajo del umbral del 5 % que activó el Schedule 13G original.
  • Las acciones son propiedad de AIGH Investment Partners, L.P. y WVP Emerging Manager Onshore Fund, LLC – AIGH Series, para los cuales AIGH Capital actúa como asesor; Hirschman firma como miembro gerente.

Conclusión para el inversor: Un antiguo poseedor con más del 5 % ha reducido su posición al 3,6 %. Aunque el grupo sigue siendo un accionista relevante, la reducción puede indicar menor convicción o un reequilibrio de cartera; la participación reducida también disminuye cualquier influencia de un único accionista en las decisiones corporativas.

제출 개요: 2025년 7월 29일, 오린 허시만(Orin Hirschman)과 AIGH 캐피털 매니지먼트 LLC가 Verastem, Inc.(VSTM)에 대한 Schedule 13G 수정안 1호를 제출했습니다. 이 수정안은 2025년 6월 30일 기준으로 Verastem의 발행 주식 중 3.6%에 해당하는 2,003,179주의 보통주에 대한 총 실질 소유권을 보고합니다.

주요 내용

  • 모든 주식은 단독 의결권 및 처분권을 보유하고 있으며, 공동 권한은 보고되지 않았습니다.
  • 항목 5에서는 그룹이 현재 “5% 이하”의 지분을 보유하고 있다고 명시하여, 원래 Schedule 13G를 촉발시킨 5% 임계치를 밑돌았음을 나타냅니다.
  • 주식은 AIGH Investment Partners, L.P.와 WVP Emerging Manager Onshore Fund, LLC – AIGH Series가 소유하며, AIGH Capital이 자문사로 활동하고, 허시만은 관리 멤버로 서명했습니다.

투자자 시사점: 5% 이상 보유자였던 그룹이 지분을 3.6%로 줄였습니다. 그룹은 여전히 중요한 주주이지만, 지분 축소는 신념 약화나 포트폴리오 재조정 신호일 수 있으며, 지분 감소는 단일 주주의 기업 의사결정 영향력도 줄입니다.

Résumé du dépôt : Le 29 juillet 2025, Orin Hirschman et AIGH Capital Management LLC ont déposé l'Amendement n° 1 au Schedule 13G concernant Verastem, Inc. (VSTM). L'amendement rapporte une propriété bénéficiaire agrégée de 2 003 179 actions ordinaires, représentant 3,6 % du capital en circulation de Verastem au 30 juin 2025.

Détails clés

  • Toutes les actions sont détenues avec un pouvoir de vote et de disposition exclusif ; aucun pouvoir partagé n'est signalé.
  • L’élément 5 indique que le groupe possède désormais « 5 pour cent ou moins » de la catégorie, ce qui signifie que la participation est tombée en dessous du seuil de 5 % qui avait déclenché le Schedule 13G initial.
  • Les actions sont détenues par AIGH Investment Partners, L.P. et WVP Emerging Manager Onshore Fund, LLC – AIGH Series, pour lesquels AIGH Capital agit en tant que conseiller ; Hirschman signe en tant que membre gestionnaire.

Conclusion pour l’investisseur : Un ancien détenteur de plus de 5 % a réduit sa position à 3,6 %. Bien que le groupe reste un actionnaire significatif, cette réduction pourrait indiquer une moindre conviction ou un rééquilibrage du portefeuille ; la participation réduite diminue également l’influence d’un seul actionnaire sur les décisions de l’entreprise.

Übersicht der Einreichung: Am 29. Juli 2025 reichten Orin Hirschman und AIGH Capital Management LLC die Änderung Nr. 1 zum Schedule 13G für Verastem, Inc. (VSTM) ein. Die Änderung meldet einen aggregierten wirtschaftlichen Anteil von 2.003.179 Stammaktien, was 3,6 % der ausstehenden Aktien von Verastem zum 30. Juni 2025 entspricht.

Wichtige Details

  • Alle Aktien werden mit alleinigem Stimm- und Verfügungsrecht gehalten; keine geteilten Rechte werden gemeldet.
  • Punkt 5 gibt an, dass die Gruppe nun „5 Prozent oder weniger“ der Klasse besitzt, was darauf hinweist, dass der Anteil unter die 5 %-Schwelle gefallen ist, die das ursprüngliche Schedule 13G ausgelöst hat.
  • Die Aktien werden von AIGH Investment Partners, L.P. und WVP Emerging Manager Onshore Fund, LLC – AIGH Series gehalten, für die AIGH Capital als Berater fungiert; Hirschman unterschreibt als geschäftsführendes Mitglied.

Investorenausblick: Ein ehemaliger Anteilseigner mit über 5 % hat seine Position auf 3,6 % reduziert. Obwohl die Gruppe weiterhin ein bedeutender Aktionär ist, könnte die Reduzierung auf geringere Überzeugung oder eine Portfolioanpassung hinweisen; der verringerte Anteil mindert zudem den Einfluss eines einzelnen Aktionärs auf Unternehmensentscheidungen.

Positive
  • Retention of 2.0 M shares (3.6 %) means the investor group still has a meaningful, though reduced, position in VSTM.
Negative
  • Stake fell below the 5 % threshold, implying the group sold shares and reducing perceived commitment and potential support for the stock.

Insights

TL;DR: Large holder cut stake below 5 %; signals diminished commitment and possible selling pressure.

The move from >5 % to 3.6 % removes AIGH/Orin Hirschman from the list of Section 13(d) “active” owners, reducing potential influence over governance and proxy outcomes. Liquidation of roughly 900 k+ shares (exact prior level not disclosed here) may create short-term supply and suggests lowered risk-adjusted return expectations. Nonetheless, retaining 2 M shares shows continued, albeit smaller, alignment. I view the development as modestly negative for sentiment but not thesis-changing.

TL;DR: Compliance-driven amendment; governance impact limited.

This filing mainly updates ownership disclosure and certifies ordinary-course intent under Rule 13d-1. No change in control or activist language appears. Governance risk is therefore minimal, and board dynamics should remain unchanged. Investors should simply note the ownership update for modeling purposes.

Panoramica della comunicazione: Il 29 luglio 2025 Orin Hirschman e AIGH Capital Management LLC hanno presentato l'Emendamento n. 1 al Schedule 13G relativo a Verastem, Inc. (VSTM). L'emendamento riporta una proprietà aggregata di 2.003.179 azioni ordinarie, pari al 3,6% del capitale sociale di Verastem al 30 giugno 2025.

Dettagli principali

  • Tutte le azioni sono detenute con potere di voto e dispositivi esclusivi; non è riportato alcun potere condiviso.
  • L'elemento 5 indica che il gruppo ora possiede “5 percento o meno” della categoria, segnalando che la quota è scesa al di sotto della soglia del 5% che ha innescato il Schedule 13G originale.
  • Le azioni sono detenute da AIGH Investment Partners, L.P. e WVP Emerging Manager Onshore Fund, LLC – AIGH Series, per i quali AIGH Capital agisce come consulente; Hirschman firma come membro amministratore.

Considerazioni per l'investitore: Un ex detentore con oltre il 5% ha ridotto la propria posizione al 3,6%. Sebbene il gruppo resti un azionista significativo, la riduzione potrebbe indicare una minore convinzione o un riequilibrio del portafoglio; la quota ridotta diminuisce inoltre qualsiasi influenza di un singolo azionista sulle decisioni aziendali.

Resumen de la presentación: El 29 de julio de 2025, Orin Hirschman y AIGH Capital Management LLC presentaron la Enmienda n.º 1 al Schedule 13G sobre Verastem, Inc. (VSTM). La enmienda reporta una propiedad agregada de 2.003.179 acciones ordinarias, representando el 3,6 % del capital social en circulación de Verastem al 30 de junio de 2025.

Detalles clave

  • Todas las acciones se mantienen con poder exclusivo de voto y disposición; no se reporta poder compartido.
  • El punto 5 indica que el grupo ahora posee “5 por ciento o menos” de la clase, señalando que la participación ha caído por debajo del umbral del 5 % que activó el Schedule 13G original.
  • Las acciones son propiedad de AIGH Investment Partners, L.P. y WVP Emerging Manager Onshore Fund, LLC – AIGH Series, para los cuales AIGH Capital actúa como asesor; Hirschman firma como miembro gerente.

Conclusión para el inversor: Un antiguo poseedor con más del 5 % ha reducido su posición al 3,6 %. Aunque el grupo sigue siendo un accionista relevante, la reducción puede indicar menor convicción o un reequilibrio de cartera; la participación reducida también disminuye cualquier influencia de un único accionista en las decisiones corporativas.

제출 개요: 2025년 7월 29일, 오린 허시만(Orin Hirschman)과 AIGH 캐피털 매니지먼트 LLC가 Verastem, Inc.(VSTM)에 대한 Schedule 13G 수정안 1호를 제출했습니다. 이 수정안은 2025년 6월 30일 기준으로 Verastem의 발행 주식 중 3.6%에 해당하는 2,003,179주의 보통주에 대한 총 실질 소유권을 보고합니다.

주요 내용

  • 모든 주식은 단독 의결권 및 처분권을 보유하고 있으며, 공동 권한은 보고되지 않았습니다.
  • 항목 5에서는 그룹이 현재 “5% 이하”의 지분을 보유하고 있다고 명시하여, 원래 Schedule 13G를 촉발시킨 5% 임계치를 밑돌았음을 나타냅니다.
  • 주식은 AIGH Investment Partners, L.P.와 WVP Emerging Manager Onshore Fund, LLC – AIGH Series가 소유하며, AIGH Capital이 자문사로 활동하고, 허시만은 관리 멤버로 서명했습니다.

투자자 시사점: 5% 이상 보유자였던 그룹이 지분을 3.6%로 줄였습니다. 그룹은 여전히 중요한 주주이지만, 지분 축소는 신념 약화나 포트폴리오 재조정 신호일 수 있으며, 지분 감소는 단일 주주의 기업 의사결정 영향력도 줄입니다.

Résumé du dépôt : Le 29 juillet 2025, Orin Hirschman et AIGH Capital Management LLC ont déposé l'Amendement n° 1 au Schedule 13G concernant Verastem, Inc. (VSTM). L'amendement rapporte une propriété bénéficiaire agrégée de 2 003 179 actions ordinaires, représentant 3,6 % du capital en circulation de Verastem au 30 juin 2025.

Détails clés

  • Toutes les actions sont détenues avec un pouvoir de vote et de disposition exclusif ; aucun pouvoir partagé n'est signalé.
  • L’élément 5 indique que le groupe possède désormais « 5 pour cent ou moins » de la catégorie, ce qui signifie que la participation est tombée en dessous du seuil de 5 % qui avait déclenché le Schedule 13G initial.
  • Les actions sont détenues par AIGH Investment Partners, L.P. et WVP Emerging Manager Onshore Fund, LLC – AIGH Series, pour lesquels AIGH Capital agit en tant que conseiller ; Hirschman signe en tant que membre gestionnaire.

Conclusion pour l’investisseur : Un ancien détenteur de plus de 5 % a réduit sa position à 3,6 %. Bien que le groupe reste un actionnaire significatif, cette réduction pourrait indiquer une moindre conviction ou un rééquilibrage du portefeuille ; la participation réduite diminue également l’influence d’un seul actionnaire sur les décisions de l’entreprise.

Übersicht der Einreichung: Am 29. Juli 2025 reichten Orin Hirschman und AIGH Capital Management LLC die Änderung Nr. 1 zum Schedule 13G für Verastem, Inc. (VSTM) ein. Die Änderung meldet einen aggregierten wirtschaftlichen Anteil von 2.003.179 Stammaktien, was 3,6 % der ausstehenden Aktien von Verastem zum 30. Juni 2025 entspricht.

Wichtige Details

  • Alle Aktien werden mit alleinigem Stimm- und Verfügungsrecht gehalten; keine geteilten Rechte werden gemeldet.
  • Punkt 5 gibt an, dass die Gruppe nun „5 Prozent oder weniger“ der Klasse besitzt, was darauf hinweist, dass der Anteil unter die 5 %-Schwelle gefallen ist, die das ursprüngliche Schedule 13G ausgelöst hat.
  • Die Aktien werden von AIGH Investment Partners, L.P. und WVP Emerging Manager Onshore Fund, LLC – AIGH Series gehalten, für die AIGH Capital als Berater fungiert; Hirschman unterschreibt als geschäftsführendes Mitglied.

Investorenausblick: Ein ehemaliger Anteilseigner mit über 5 % hat seine Position auf 3,6 % reduziert. Obwohl die Gruppe weiterhin ein bedeutender Aktionär ist, könnte die Reduzierung auf geringere Überzeugung oder eine Portfolioanpassung hinweisen; der verringerte Anteil mindert zudem den Einfluss eines einzelnen Aktionärs auf Unternehmensentscheidungen.

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2025

 

Commission file number: 001-40231

 

 

 

Universe Pharmaceuticals INC

 

 

 

265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F             Form 40-F

 

 

 

 

 

In connection with the 2025 Annual General Meeting of Shareholders of Universe Pharmaceuticals INC, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), the Company hereby furnishes the following documents:

 

Exhibits

 

Exhibit No.   Description
99.1   Notice and Proxy Statement of 2025 Annual General Meeting of Shareholders, dated July 29, 2025, to be mailed to the shareholders of the Company in connection with the 2025 Annual General Meeting of Shareholders of the Company
99.2   Form of Proxy Card to be mailed to shareholders of the Company for use in connection with the 2025 Annual General Meeting of Shareholders of the Company

 

1 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Universe Pharmaceuticals INC.
   
Date: July 29, 2025 By: /s/ Gang Lai
    Gang Lai
    Chief Executive Officer

 

 

2

 

FAQ

How many Verastem (VSTM) shares does Orin Hirschman now hold?

The filing lists 2,003,179 common shares beneficially owned.

What percentage of Verastem's outstanding shares is represented by this stake?

The position equals 3.6 % of the company’s common stock.

Why was an amended Schedule 13G/A filed?

Item 5 shows ownership dropped below 5 %, requiring an update to the original 13G.

Who are the reporting persons in this filing?

AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman.

What is the CUSIP number for Verastem common stock?

The CUSIP is 92337C203.

When did the event triggering the filing occur?

The relevant event date is 30 June 2025; the document was signed 29 July 2025.

Do the reporting persons share voting or dispositive power with others?

No. The filing reports sole voting and dispositive power over all disclosed shares.
Universe Pharmaceuticals Inc

NASDAQ:UPC

UPC Rankings

UPC Latest News

UPC Latest SEC Filings

UPC Stock Data

2.06M
559.87k
0.91%
3.7%
0.37%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
China
Ji'An